Atavistik Bio Enhances SAB with Dr. William Sellers

Atavistik Bio, a biotechnology company specializing in next-generation precision allosteric therapeutics, has announced the appointment of Dr. William Sellers to its Scientific Advisory Board. Dr. Sellers, a distinguished cancer researcher, is a core institute member and director of the cancer program at the Broad Institute, as well as a professor at Dana-Farber Cancer Institute and Harvard Medical School. His extensive experience in cancer biology and therapeutics supports Atavistik Bio's mission to advance its pipeline of innovative small molecule medicines. Under this guidance, the company is set to transition their lead asset, ATV-1601, a selective inhibitor targeting AKT1 E17K-driven cancers, into clinical trials anticipated in early 2025. Atavistik Bio, supported by investors such as The Column Group, is dedicated to addressing serious unmet patient needs through precision therapeutics.